Limits...
Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer.

Sekine I, Sumi M, Satouchi M, Tsujino K, Nishio M, Kozuka T, Niho S, Nihei K, Yamamoto N, Harada H, Ishikura S, Tamura T - Cancer Sci. (2016)

Bottom Line: The response rate was 95%.The median overall survival (OS) has not been reached yet, and the 5-year OS rate (CI) was 57.8% (35.2-80.4%).In conclusion, EP-TRT followed by AP therapy was well-tolerated, although a large number of patients required G-CSF support.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH

Related in: MedlinePlus

Progression‐free survival (n = 21).
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4814250&req=5

cas12875-fig-0001: Progression‐free survival (n = 21).

Mentions: The tumor response was not assessable in 1 patient because she refused to receive subsequent therapy after one cycle of AP therapy. Among the remaining 20 patients, 2 CR and 18 partial responses were observed, and, therefore, the ORR in the 21 patients was 95% (95% CI, 76.2–99.9%). The median progression‐free survival (PFS) was 41.9 months (95% CI, 0–102 months), and the 3‐year and 5‐year PFS rates were 52.4% (95% CI, 31.0–73.8%) and 41.9% (95% CI, 20.4–63.4%), respectively (Fig. 1). The median overall survival (OS) has not been reached yet, and the 3‐year and 5‐year OS rates were 63.6% (95% CI, 41.8–85.4%) and 57.8% (95% CI, 35.2–80.4%), respectively (Fig. 2).


Feasibility study of chemoradiotherapy followed by amrubicin and cisplatin for limited-disease small cell lung cancer.

Sekine I, Sumi M, Satouchi M, Tsujino K, Nishio M, Kozuka T, Niho S, Nihei K, Yamamoto N, Harada H, Ishikura S, Tamura T - Cancer Sci. (2016)

Progression‐free survival (n = 21).
© Copyright Policy - creativeCommonsBy-nc-nd
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4814250&req=5

cas12875-fig-0001: Progression‐free survival (n = 21).
Mentions: The tumor response was not assessable in 1 patient because she refused to receive subsequent therapy after one cycle of AP therapy. Among the remaining 20 patients, 2 CR and 18 partial responses were observed, and, therefore, the ORR in the 21 patients was 95% (95% CI, 76.2–99.9%). The median progression‐free survival (PFS) was 41.9 months (95% CI, 0–102 months), and the 3‐year and 5‐year PFS rates were 52.4% (95% CI, 31.0–73.8%) and 41.9% (95% CI, 20.4–63.4%), respectively (Fig. 1). The median overall survival (OS) has not been reached yet, and the 3‐year and 5‐year OS rates were 63.6% (95% CI, 41.8–85.4%) and 57.8% (95% CI, 35.2–80.4%), respectively (Fig. 2).

Bottom Line: The response rate was 95%.The median overall survival (OS) has not been reached yet, and the 5-year OS rate (CI) was 57.8% (35.2-80.4%).In conclusion, EP-TRT followed by AP therapy was well-tolerated, although a large number of patients required G-CSF support.

View Article: PubMed Central - PubMed

Affiliation: Division of Internal Medicine and Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.

Show MeSH
Related in: MedlinePlus